Long-term Study to Evaluate Safety and Persistence of GF-CART01

Enrolling by invitation

Conditions studied: DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma (FL), Primary Mediastinal Large B-Cell Lymphoma, High Grade B Cell Lymphoma

In brief

The goal of this observational study is to learn about the long-term safety of GF-CART01 after cell infusion up to 15 years.

Key facts

Study ID

NCT06985576

Run by

GenomeFrontier Therapeutics TW Co., Ltd.

People needed

18

Starts

2026-02-26

Expected to finish

2041-05-01

Last updated by the study team

2026-06-11

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects previously enrolled in the study of GF-CART01 (Protocol No.: GF-01-01) and received GF-CART01 infusion
• Subjects or their legal guardians must volunteer to participate in the study and sign the informed consent
• Willingness and ability to comply with protocol-stated requirements, instructions, and restrictions in the investigator's judgement
• Exclusion Criteria: None

Where it is running

• National Taiwan University Hospital — Taipei, Taiwan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.